Abstract 5699
Background
TNBC accounts for approximately 15% to 20% of breast cancers. Patients with TNBC tend to have a worse prognosis and are typically diagnosed at a younger age compared with patients with other breast cancer subtypes. Chemotherapy has been the foundation of care for patients with mTNBC, but new targeted treatment (tx) options are now available (olaparib, veliparib, atezolizumab). The IMpassion130 study showed that the combination of atezolizumab + nab-paclitaxel (pac) improved efficacy outcomes in 1L mTNBC. This analysis was conducted to assess the characteristics of patients receiving taxanes in current US clinical practice.
Methods
A total of 2250 female patients newly diagnosed with mTNBC and who received 1L tx between 2005 and 2015 were identified in the Truven MarketScan database. Descriptive statistics were used to summarize baseline characteristics. Multivariate logistic regression models were used to identify independent predictors of treatment choice. Models included all prognostic variables.
Results
The median age of patients at 1L tx for mTNBC was 58 years. Most patients lived in metropolitan areas (86%) and were covered by commercial health insurance (74%). Taxane-containing regimens accounted for 54% of all 1L tx, with 23% receiving monotherapy and 26% receiving combination. nab-Pac was most commonly given as a single agent (64%), whereas pac and docetaxel were more commonly given in combination with other agents (62% and 67%, respectively). Single-agent vs combination taxane use, as well as the use of nab-pac regimens (vs docetaxel or pac) increased after 2010 compared with prior to 2010. Patients enrolled in a health maintenance organization plan were less likely to receive nab-pac than pac (odds ratio [OR], 0.41 [0.21-0.79]) or docetaxel (OR, 0.25 [0.12-0.51]). Other factors, such as comorbidities and number of metastatic sites, were not clearly associated with any specific taxane monotherapy tx.
Conclusions
Taxanes were the most common tx choice for 1L mTNBC. Patient characteristics were similar among patients who received pac and nab-pac monotherapy, suggesting that they are prescribed interchangeably when reimbursed by insurance.
Clinical trial identification
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Chris Lum, PhD, of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
J. O’Shaughnessy: Honoraria (self): AbbVie Inc.; Honoraria (self): Agendia; Honoraria (self): Amgen Biotechnology; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Eisai; Honoraria (self): Genentech; Honoraria (self): Genomic Health; Honoraria (self): GRAIL; Honoraria (self): Immunomedics; Honoraria (self): Heron Therapeautics; Honoraria (self): Ipsen Biopharmaceuticals; Honoraria (self): Jounce Therapeutics; Honoraria (self): Lilly; Honoraria (self): Merck; Honoraria (self): Myriad; Honoraria (self): Novartis; Honoraria (self): Ondonate Therapeutics; Honoraria (self): Pfizer; Honoraria (self): Puma Biotechnology; Honoraria (self): Seattle Genetics; Honoraria (self): Syndax Pharmaceuticals. L.A. Emens: Officer / Board of Directors: Society for Immunotherapy of Cancer (SITC); Honoraria (self): Abbvie; Honoraria (self): Amgen; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self): Celgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Honoraria (self): Gritstone; Honoraria (self): Medimmune; Honoraria (institution), Travel / Accommodation / Expenses: Macrogenics; Non-remunerated activity/ies, No Compensation: eTHeRNA; Travel / Accommodation / Expenses: Novartis; Honoraria (self): Peregrine; Honoraria (self), Travel / Accommodation / Expenses: Replimune; Honoraria (self): Syndax; Honoraria (self): Vaccinex; Research grant / Funding (institution): Aduro Biotech; Research grant / Funding (institution): Breast Cancer Research Foundation; Research grant / Funding (institution): Corvus; Research grant / Funding (institution): Department of Defense; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): HeritX, Inc.; Research grant / Funding (institution): Maxcyte; Honoraria (self), Travel / Accommodation / Expenses: Bristol Meyers Squibb; Research grant / Funding (institution): Merck; Licensing / Royalties, IND Licensing/vaccine <25K: Aduro. S. Chui: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. K. Russell: Full / Part-time employment: F. Hoffmann-La Roche, Ltd. S. Lin: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. C. Flores Avile: Full / Part-time employment: Genesis Research. P. Luhn: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche/Genentech. A. Schneeweiss: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Molecular Partner; Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self), Travel / Accommodation / Expenses: Pfizer; Honoraria (self): Novartis; Honoraria (self): MSD; Honoraria (self): Tesaro; Honoraria (self): Lilly.
Resources from the same session
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract